Technology evaluation: FluINsure, ID Biomedical

Curr Opin Mol Ther. 2004 Apr;6(2):212-20.

Abstract

ID Biomedical (formerly Intellivax International) is developing a trivalent nasal influenza vaccine, FluINsure, for the potential treatment of influenza. The vaccine is currently in phase II clinical trials.

Publication types

  • Evaluation Study

MeSH terms

  • Administration, Intranasal
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Humans
  • Influenza Vaccines* / adverse effects
  • Influenza Vaccines* / chemistry
  • Influenza Vaccines* / therapeutic use
  • Influenza, Human / mortality
  • Influenza, Human / prevention & control*
  • Patents as Topic
  • Structure-Activity Relationship

Substances

  • Influenza Vaccines